Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community-Institutional Relations | 2 | 2020 | 209 | 0.780 |
Why?
|
| Antitubercular Agents | 4 | 2024 | 1380 | 0.660 |
Why?
|
| Indians, North American | 2 | 2020 | 354 | 0.650 |
Why?
|
| Tuberculosis | 4 | 2024 | 2011 | 0.620 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2024 | 941 | 0.610 |
Why?
|
| Clofazimine | 2 | 2024 | 39 | 0.450 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 951 | 0.380 |
Why?
|
| Particulate Matter | 8 | 2017 | 2621 | 0.330 |
Why?
|
| DNA, Mitochondrial | 4 | 2019 | 872 | 0.320 |
Why?
|
| Peru | 4 | 2024 | 888 | 0.310 |
Why?
|
| Tuberculosis, Pulmonary | 4 | 2024 | 836 | 0.300 |
Why?
|
| Epigenesis, Genetic | 6 | 2019 | 3828 | 0.250 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 5886 | 0.230 |
Why?
|
| Lost to Follow-Up | 1 | 2024 | 124 | 0.220 |
Why?
|
| Air Pollution | 5 | 2017 | 2378 | 0.210 |
Why?
|
| Rifampin | 1 | 2024 | 350 | 0.200 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2024 | 1911 | 0.200 |
Why?
|
| DNA Methylation | 6 | 2019 | 4426 | 0.190 |
Why?
|
| Fetal Blood | 2 | 2019 | 1361 | 0.180 |
Why?
|
| New Mexico | 1 | 2019 | 80 | 0.170 |
Why?
|
| Arizona | 1 | 2019 | 108 | 0.170 |
Why?
|
| Utah | 1 | 2019 | 130 | 0.170 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2019 | 100 | 0.160 |
Why?
|
| Vitamin B 6 | 2 | 2017 | 237 | 0.160 |
Why?
|
| Environmental Exposure | 3 | 2017 | 4546 | 0.140 |
Why?
|
| Vitamin B 12 | 2 | 2017 | 529 | 0.140 |
Why?
|
| Folic Acid | 3 | 2019 | 1336 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 12250 | 0.130 |
Why?
|
| Genome, Human | 2 | 2019 | 4441 | 0.120 |
Why?
|
| Heart Rate | 2 | 2017 | 4209 | 0.120 |
Why?
|
| Vitamin B Complex | 1 | 2017 | 299 | 0.120 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2014 | 62 | 0.120 |
Why?
|
| Air Pollutants | 3 | 2017 | 2920 | 0.110 |
Why?
|
| Soot | 1 | 2015 | 219 | 0.110 |
Why?
|
| Aging | 4 | 2016 | 8729 | 0.110 |
Why?
|
| DNA | 2 | 2019 | 7210 | 0.110 |
Why?
|
| Birth Weight | 2 | 2019 | 2122 | 0.110 |
Why?
|
| Bradycardia | 1 | 2015 | 305 | 0.100 |
Why?
|
| Lead | 1 | 2019 | 882 | 0.100 |
Why?
|
| CpG Islands | 4 | 2019 | 1206 | 0.100 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2015 | 348 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 1063 | 0.100 |
Why?
|
| Autonomic Nervous System | 1 | 2017 | 707 | 0.100 |
Why?
|
| Flavonoids | 1 | 2015 | 447 | 0.090 |
Why?
|
| Maternal Exposure | 1 | 2019 | 1096 | 0.090 |
Why?
|
| Patient Participation | 1 | 2020 | 1444 | 0.090 |
Why?
|
| Vehicle Emissions | 1 | 2015 | 651 | 0.090 |
Why?
|
| Middle Aged | 12 | 2024 | 223233 | 0.080 |
Why?
|
| Aged | 10 | 2024 | 171319 | 0.080 |
Why?
|
| Heart Conduction System | 1 | 2015 | 1008 | 0.080 |
Why?
|
| Cohort Studies | 6 | 2024 | 41718 | 0.080 |
Why?
|
| Environmental Pollutants | 1 | 2019 | 1296 | 0.080 |
Why?
|
| Mastectomy, Segmental | 1 | 2014 | 974 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 1946 | 0.080 |
Why?
|
| Male | 17 | 2024 | 364203 | 0.080 |
Why?
|
| Oxidative Stress | 2 | 2019 | 3139 | 0.080 |
Why?
|
| Particle Size | 3 | 2017 | 1633 | 0.080 |
Why?
|
| Adult | 13 | 2024 | 223317 | 0.080 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 2183 | 0.080 |
Why?
|
| Female | 17 | 2024 | 396660 | 0.070 |
Why?
|
| Occupational Diseases | 1 | 2016 | 1456 | 0.070 |
Why?
|
| Humans | 25 | 2024 | 767040 | 0.070 |
Why?
|
| Placenta | 1 | 2017 | 1726 | 0.070 |
Why?
|
| Gestational Age | 1 | 2016 | 3618 | 0.070 |
Why?
|
| Young Adult | 6 | 2024 | 59980 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2017 | 3445 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 3232 | 0.060 |
Why?
|
| Prospective Studies | 8 | 2024 | 54886 | 0.060 |
Why?
|
| Kazakhstan | 1 | 2024 | 19 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 59548 | 0.060 |
Why?
|
| Pyrazinamide | 1 | 2024 | 60 | 0.060 |
Why?
|
| Adolescent | 5 | 2024 | 89046 | 0.060 |
Why?
|
| Cycloserine | 1 | 2024 | 118 | 0.060 |
Why?
|
| Nitroimidazoles | 1 | 2024 | 118 | 0.050 |
Why?
|
| Oxazoles | 1 | 2024 | 198 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 26325 | 0.050 |
Why?
|
| Fetal Development | 2 | 2019 | 777 | 0.050 |
Why?
|
| Mitochondria | 1 | 2015 | 3678 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2016 | 6421 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2024 | 65295 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 2105 | 0.040 |
Why?
|
| Risk Factors | 2 | 2024 | 74886 | 0.040 |
Why?
|
| Cognition | 1 | 2018 | 7059 | 0.040 |
Why?
|
| Epigenomics | 2 | 2017 | 959 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2015 | 8531 | 0.040 |
Why?
|
| Infant, Newborn | 4 | 2024 | 26396 | 0.040 |
Why?
|
| Pregnancy | 5 | 2020 | 30238 | 0.040 |
Why?
|
| Inflammation | 1 | 2017 | 10869 | 0.030 |
Why?
|
| Diet | 1 | 2015 | 8089 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 2021 | 713 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2024 | 4026 | 0.030 |
Why?
|
| Mexico | 1 | 2019 | 769 | 0.030 |
Why?
|
| Hypertension | 1 | 2015 | 8615 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 793 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 6310 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2017 | 8732 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1587 | 0.030 |
Why?
|
| Feces | 1 | 2019 | 1508 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 856 | 0.020 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2015 | 270 | 0.020 |
Why?
|
| Methylation | 1 | 2015 | 1076 | 0.020 |
Why?
|
| Fetus | 1 | 2019 | 1878 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2020 | 2505 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 976 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2015 | 548 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 15645 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2017 | 1366 | 0.020 |
Why?
|
| Fasting | 1 | 2016 | 1607 | 0.020 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 12790 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 1788 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2015 | 1312 | 0.020 |
Why?
|
| Child | 3 | 2024 | 80771 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 2850 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2021 | 3797 | 0.020 |
Why?
|
| Linear Models | 1 | 2017 | 5875 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 1422 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 21178 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2019 | 2538 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 2900 | 0.020 |
Why?
|
| Menopause | 1 | 2014 | 1655 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 3552 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 5796 | 0.020 |
Why?
|
| Boston | 1 | 2017 | 9360 | 0.010 |
Why?
|
| Risk | 1 | 2016 | 9606 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2017 | 6409 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6513 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 39317 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2020 | 22254 | 0.010 |
Why?
|
| Smoking | 1 | 2019 | 9081 | 0.010 |
Why?
|
| Infant | 1 | 2024 | 36485 | 0.010 |
Why?
|
| Genomics | 1 | 2018 | 5924 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2024 | 42606 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 20169 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2019 | 13048 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 14766 | 0.010 |
Why?
|
| Survival Rate | 1 | 2015 | 12823 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 12536 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 10393 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2016 | 81659 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 9410 | 0.010 |
Why?
|
| Time Factors | 1 | 2016 | 40154 | 0.010 |
Why?
|
| Prognosis | 1 | 2015 | 29963 | 0.010 |
Why?
|
| HIV Infections | 1 | 2020 | 17542 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11872 | 0.010 |
Why?
|
Concepts
(144)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(26)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_